Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab
出版年份 2023 全文链接
标题
Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab
作者
关键词
-
出版物
PATHOLOGY RESEARCH AND PRACTICE
Volume -, Issue -, Pages 154917
出版商
Elsevier BV
发表日期
2023-11-04
DOI
10.1016/j.prp.2023.154917
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic Significance of p16 Protein Expression in Breast Cancer
- (2021) MAGDI M. SALIH et al. IN VIVO
- IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
- (2020) Yiwei Tong et al. Frontiers in Oncology
- Expression of Ki67 and p53 Proteins: Breast Cancer Aggressivity Markers in Brazilian Young Patients
- (2020) Mayara Bocchi et al. Journal of Adolescent and Young Adult Oncology
- Androgen Receptor in Breast Cancer: From Bench to Bedside
- (2020) Mengyao Chen et al. Frontiers in Endocrinology
- Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
- (2020) Abirami Sivapiragasam et al. Cancer Medicine
- Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy
- (2019) Yi-wei Tong et al. OncoTargets and Therapy
- Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
- (2019) Lajos Pusztai et al. LANCET ONCOLOGY
- An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
- (2019) Cedric Darini et al. Nature Communications
- Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
- (2019) Afshin Derakhshani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer
- (2019) Nanis Shawky Holah et al. JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY
- Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
- (2018) Armando E. Giuliano et al. ANNALS OF SURGICAL ONCOLOGY
- Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
- (2018) Panagiotis F. Christopoulos et al. CANCER TREATMENT REVIEWS
- Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
- (2018) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Expression of p16 and SATB1 in Invasive Ductal Breast Cancer – A Preliminary Study
- (2018) CHRISTOPHER KOBIERZYCKI et al. IN VIVO
- P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling
- (2018) Le Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer
- (2018) Soo Youn Bae et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes
- (2017) Elise Furet et al. Oncotarget
- PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
- (2017) Daphne Gschwantler-Kaulich et al. PLoS One
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- (2016) María F. Mercogliano et al. CLINICAL CANCER RESEARCH
- ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
- (2016) Patricia V Elizalde et al. ENDOCRINE-RELATED CANCER
- Increased expression of senescence markers p14ARFand p16INK4ain breast cancer is associated with an increased risk of disease recurrence and poor survival outcome
- (2016) Rahmawati Pare et al. HISTOPATHOLOGY
- Practical issues in the application of p16 immunohistochemistry in diagnostic pathology
- (2016) Aparna Mahajan HUMAN PATHOLOGY
- BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer
- (2016) Yong Hwa Eom et al. Journal of Breast Cancer
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation
- (2016) Marina Saisana et al. Oncotarget
- p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer
- (2016) Patrick Lebok et al. Oncotarget
- Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer
- (2015) Kerem Okutur et al. Asian Pacific Journal of Cancer Prevention
- A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
- (2015) Otília Menyhart et al. CURRENT CANCER DRUG TARGETS
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
- (2015) Inês de Paula Costa Monteiro et al. PHARMACOGENOMICS
- The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis
- (2015) Shunchao Yan et al. OncoTargets and Therapy
- Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients
- (2015) Sandra Heskamp et al. PLoS One
- Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
- (2014) Thuy Vu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
- (2014) Maurizio Scaltriti et al. CLINICAL CANCER RESEARCH
- Positive Expression of Insulin-Like Growth Factor-1 Receptor Is Associated with a Positive Hormone Receptor Status and a Favorable Prognosis in Breast Cancer
- (2014) Su-Jin Shin et al. Journal of Breast Cancer
- Longer Survival in Patients with Breast Cancer with Cyclin D1 Over-Expression after Tumor Recurrence: Longer, but Occupied with Disease
- (2014) Jaesik Chung et al. Journal of Breast Cancer
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- HER2-positive breast cancer patients: correlation between mammographic and pathological findings
- (2014) S. Radenkovic et al. RADIATION PROTECTION DOSIMETRY
- Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
- (2014) Sahil Ahmad et al. Scientific Reports
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
- (2013) Ana Catarina Pinto et al. BREAST
- Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
- (2013) Y H Park et al. BRITISH JOURNAL OF CANCER
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
- (2013) André Robidoux et al. LANCET ONCOLOGY
- Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
- (2013) Filippo Montemurro et al. Molecular Oncology
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype
- (2012) Eleni Mylona et al. HISTOPATHOLOGY
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
- (2012) C. V. Pastuskovas et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
- (2012) Mattia Barbareschi et al. VIRCHOWS ARCHIV
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- Mucins in the pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy
- (2011) Partha Mukhopadhyay et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
- (2011) Rinat Yerushalmi et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors
- (2011) C Romagosa et al. ONCOGENE
- Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma
- (2010) Sondes Karray-Chouayekh et al. ACTA HISTOCHEMICA
- Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
- (2010) Hermien Hartog et al. BREAST CANCER RESEARCH AND TREATMENT
- Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer
- (2010) Rulla M. Tamimi et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy
- (2010) Rohit Bhargava et al. CANCER
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
- (2010) Donata Micello et al. VIRCHOWS ARCHIV
- The Membrane Mucin Muc4 Inhibits Apoptosis Induced by Multiple Insults via ErbB2-Dependent and ErbB2-Independent Mechanisms
- (2009) H. C. Workman et al. CANCER RESEARCH
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- p27Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis
- (2009) Xiaoxiang Guan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
- (2008) Michel Marty et al. EUROPEAN JOURNAL OF CANCER
- The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)
- (2008) Bart Cornelissen et al. NUCLEAR MEDICINE AND BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now